Market Cap 432.95M
Revenue (ttm) 0.00
Net Income (ttm) -158.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 690,366
Avg Vol 446,764
Day's Range N/A - N/A
Shares Out 80.03M
Stochastic %K 34%
Beta 0.38
Analysts Sell
Price Target $8.00

Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection....

Industry: Biotechnology
Sector: Healthcare
Phone: 857 284 8891
Address:
225 Franklin Street, Suite 2100, Boston, United States
Biotech_Pharma_Investor
Biotech_Pharma_Investor May. 13 at 3:21 PM
$AVIR why the dip today?
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor May. 13 at 3:03 PM
$AVIR why the drop today?
0 · Reply
laaarsas
laaarsas May. 13 at 2:41 PM
$AVIR why down today? Unclear to me
1 · Reply
Following_the_trend
Following_the_trend May. 13 at 2:24 PM
$AVIR Ok, finally a starter here.
0 · Reply
focafoca99
focafoca99 May. 13 at 11:28 AM
$AVIR showcases three abstracts accepted for presentation at EASL 2026.
0 · Reply
Olivia_Strickland
Olivia_Strickland May. 12 at 10:21 PM
$AVIR down 5.27% AH after a Q1 print that technically beat by 2 cents, because apparently a 2-cent beat on a 57-cent loss is the new sell signal. session vol nothing special at 1.19x avg and the YTD is still +58% so the chart isn't broken, just the AH crowd doing AH crowd things at $5.20. dry take, this fills the red candle by mid-morning once someone actually pulls up the deck. anyone else think the post-earnings fade on small biotechs has become its own setup, or am I reading too much into a $440M cap moving on 309k shares? live AH tape + alerts: https://tapeboard.com/chart/AVIR?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=avir-ah-dn-tape
0 · Reply
MarketBeat
MarketBeat May. 12 at 10:08 PM
https://marketbeat.com/a/8651109/ $AVIR Atea Pharmaceuticals Q1 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 12 at 9:32 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-atea-pharmaceuticals-inc-stock/ $AVIR Atea Pharmaceuticals Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 12 at 9:29 PM
$AVIR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.57 down -42.50% YoY • Atea Pharmaceuticals Inc expects to report topline results for its C-BEYOND HCV trial in mid-2026 and C-FORWARD at year-end 2026, targeting March 2027 for NDA submission, with AT-587 entering Phase 1 in mid-2026.
0 · Reply
Cutlass
Cutlass May. 12 at 8:59 PM
$AVIR Two's are gone - 😒
1 · Reply
Latest News on AVIR
Atea Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 22 hours ago

Atea Pharmaceuticals Earnings Call Transcript: Q1 2026


Atea Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 5, 2026, 4:30 PM EST - 2 months ago

Atea Pharmaceuticals Earnings Call Transcript: Q4 2025


Atea Pharmaceuticals presents preclinical results of AT-587

2026-02-24T12:40:00.000Z - 2 months ago

Atea Pharmaceuticals presents preclinical results of AT-587


Atea Pharmaceuticals to highlight strategic priorities for FY26

2026-01-08T12:17:39.000Z - 4 months ago

Atea Pharmaceuticals to highlight strategic priorities for FY26


Atea Pharmaceuticals Transcript: Status Update

Nov 13, 2025, 10:00 AM EST - 6 months ago

Atea Pharmaceuticals Transcript: Status Update


Atea Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 6 months ago

Atea Pharmaceuticals Earnings Call Transcript: Q3 2025


Atea Pharmaceuticals announces presentation of data on BEM, RZR

2025-11-07T13:10:51.000Z - 6 months ago

Atea Pharmaceuticals announces presentation of data on BEM, RZR


Atea Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Atea Pharmaceuticals Earnings Call Transcript: Q2 2025


Atea Pharmaceuticals Transcript: Status Update

May 14, 2025, 10:00 AM EDT - 1 year ago

Atea Pharmaceuticals Transcript: Status Update


Atea Pharmaceuticals to host hepatitis C virus KOL panel

2025-05-01T11:36:00.000Z - 1 year ago

Atea Pharmaceuticals to host hepatitis C virus KOL panel


Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c)

2025-03-06T21:36:49.000Z - 1 year ago

Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c)


Atea Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 6, 2025, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Earnings Call Transcript: Q4 2024


Atea Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Atea Pharmaceuticals Earnings Call Transcript: Q3 2024


Atea Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Atea Pharmaceuticals Earnings Call Transcript: Q2 2024


Atea Pharmaceuticals Earnings Call Transcript: Q1 2024

May 14, 2024, 4:30 PM EDT - 2 years ago

Atea Pharmaceuticals Earnings Call Transcript: Q1 2024


Atea Pharmaceuticals Earnings Call Transcript: Q4 2023

Feb 28, 2024, 4:30 PM EST - 2 years ago

Atea Pharmaceuticals Earnings Call Transcript: Q4 2023


Biotech_Pharma_Investor
Biotech_Pharma_Investor May. 13 at 3:21 PM
$AVIR why the dip today?
1 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor May. 13 at 3:03 PM
$AVIR why the drop today?
0 · Reply
laaarsas
laaarsas May. 13 at 2:41 PM
$AVIR why down today? Unclear to me
1 · Reply
Following_the_trend
Following_the_trend May. 13 at 2:24 PM
$AVIR Ok, finally a starter here.
0 · Reply
focafoca99
focafoca99 May. 13 at 11:28 AM
$AVIR showcases three abstracts accepted for presentation at EASL 2026.
0 · Reply
Olivia_Strickland
Olivia_Strickland May. 12 at 10:21 PM
$AVIR down 5.27% AH after a Q1 print that technically beat by 2 cents, because apparently a 2-cent beat on a 57-cent loss is the new sell signal. session vol nothing special at 1.19x avg and the YTD is still +58% so the chart isn't broken, just the AH crowd doing AH crowd things at $5.20. dry take, this fills the red candle by mid-morning once someone actually pulls up the deck. anyone else think the post-earnings fade on small biotechs has become its own setup, or am I reading too much into a $440M cap moving on 309k shares? live AH tape + alerts: https://tapeboard.com/chart/AVIR?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=avir-ah-dn-tape
0 · Reply
MarketBeat
MarketBeat May. 12 at 10:08 PM
https://marketbeat.com/a/8651109/ $AVIR Atea Pharmaceuticals Q1 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 12 at 9:32 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-atea-pharmaceuticals-inc-stock/ $AVIR Atea Pharmaceuticals Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 12 at 9:29 PM
$AVIR Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.57 down -42.50% YoY • Atea Pharmaceuticals Inc expects to report topline results for its C-BEYOND HCV trial in mid-2026 and C-FORWARD at year-end 2026, targeting March 2027 for NDA submission, with AT-587 entering Phase 1 in mid-2026.
0 · Reply
Cutlass
Cutlass May. 12 at 8:59 PM
$AVIR Two's are gone - 😒
1 · Reply
Cutlass
Cutlass May. 12 at 8:36 PM
$AVIR Plenty of cash ✍️👀📣
0 · Reply
focafoca99
focafoca99 May. 12 at 8:29 PM
$AVIR released its Q1 2026 financial results in a press release attached to the 8‑K.
0 · Reply
Cutlass
Cutlass May. 12 at 8:07 PM
$AVIR The global Phase 3 program consists of two open-label, controlled trials: C-BEYOND (conducted in North America): Enrollment completed in December 2025 with more than 880 patients; topline results expected mid-2026. C-FORWARD (conducted outside North America): Enrollment on track for completion mid-2026; topline results expected around year-end 2026.
0 · Reply
BillionerOfKing
BillionerOfKing May. 1 at 10:21 AM
$AVIR Current Stock Price: $5.51 Contracts to trade: $5.0 AVIR May 15 2026 Call Entry: $0.91 Exit: $1.70 ROI: 87% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
laaarsas
laaarsas Apr. 11 at 3:45 PM
$AVIR if ph3 hits what share price will we see?
1 · Reply
laaarsas
laaarsas Apr. 9 at 2:12 PM
$AVIR so what do ppl expect here?
0 · Reply
Merlintrader
Merlintrader Apr. 5 at 6:38 AM
$AVIR https://www.merlintrader.com/atea-pharmaceuticals-avir-deep-dive/
1 · Reply
SuperGreenToday
SuperGreenToday Apr. 2 at 5:29 PM
$AVIR Share Price: $5.78 Contract Selected: Oct 16, 2026 $5 Calls Buy Zone: $0.85 – $1.05 Target Zone: $1.60 – $1.95 Potential Upside: 77% ROI Time to Expiration: 196 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
laaarsas
laaarsas Apr. 2 at 9:58 AM
$AVIR Lol I just ran some numbers. Total pts regardless of adherece in ph2 was 259. 222 of them non-cirrhotic, leaves 37 pts cirrhotic. 245/259 pts had SVR12. Means 14 failed. In non-cirr, it was 215/222. Leaves 7 left i cirrhotic. Meaning only 30/37 had SVR in cirrhotic regardless of adherecence. This is AWFULLY bad. And look how the company presents data. Shows non-cirr and all subgroups. Fkn scammers. Pieces of shit. Gfto. This should be criminal. It's fkn misleading ppl who are not as smart as me and can see this. It should be illegal. What they should show is that only 81% has SVR12 in cirrhotics in what is the mITT in C-BEYOND. Will you salvage that with 12wk instead of 8wk? Not likely. Not impossible. But not likely. Stinky.
0 · Reply
laaarsas
laaarsas Apr. 2 at 9:47 AM
$AVIR I change my mind again. No granular data from phase 2 on regardless of adherence. 9 more pts failed in that group compared to PE. Most likely majority was in cirrhosis, otherwise they would have showed that it was not. Cirrhosis still mega risk here. Far away from convinced. Cirrhosis high risk of bad data. 12wk might not salvage. Highrisk play. Stay away or low-sized bet.
0 · Reply
laaarsas
laaarsas Apr. 2 at 9:07 AM
$AVIR Risky play. Cirrhosis data is kinda stinky. Too bad. Stay away or only minor position.
1 · Reply
laaarsas
laaarsas Apr. 2 at 8:48 AM
$AVIR How do you think market will react if study overall is good but there is failure in cirrhotics compated to ctrl?
1 · Reply